Introduction {#Sec1}
============

Castleman disease (CD) or angio-follicular hyperplasia is a rare non-malignant lymphoproliferation of undetermined origin. CD diagnosis is difficult and often delayed because of insidious onset, low awareness and clinical heterogeneity. Two major disease phenotypes can be distinguished: unicentric CD (UCD), with involved lymph node(s) affecting a single station, and multicentric CD (MCD), with multiple lymph nodes and frequent inflammatory systemic symptoms \[[@CR1]\]. The UCD phenotype is the most frequently reported in children and has the most favourable outcome \[[@CR2]\].

Diagnosis confirmation is based on histopathological findings in an involved lymph node. The hyaline vascular (HV) type is characterized by abnormal germinal centres penetrated by hyalinised vessels and associated with abnormal follicular dendritic cells. The plasma cell variant (PCV) shows normal or enlarged germinal centres associated with interfollicular plasma cell infiltration. Symptomatic CD is often associated with increased production of interleukin 6 (IL-6) \[[@CR3]\]. CD is also classified according to the presence or absence of human herpesvirus 8 (HHV-8); the association is clearly established in immune-compromised adults, the most frequent cause being HIV infection.

We attempted to survey all cases of paediatric CD identified to date in France to set up a national registry aiming to improve CD early recognition, treatment and follow-up, within the context of a new reference centre (<http://www.castleman.fr>).

Methods {#Sec2}
=======

In 2016, we e-mailed a questionnaire to members of the French paediatric immunohaematology society, the French paediatric rheumatology society and the French Reference Centre for Castleman Disease to retrospectively collect information from medical charts of patients with paediatric CD (see Additional file [1](#MOESM1){ref-type="media"}).

We included all patients with a diagnosis of UCD or MCD who presented the first symptoms before age 18 years. Patients were required to have a diagnosis based on the pathological analysis of a lymph node biopsy of an affected area with the specific pathological criteria that we described previously.

Collected information included patient's demographic information, age at first symptoms, age at diagnosis, clinical, biological and pathological findings, immunological profile with HHV-8 and HIV infection status, treatment strategy, clinical outcome and the speciality of the physicians involved. To better assess the burden and duration of the diagnostic delay, all other diagnostic procedures were reviewed (biopsies, CT scan, ultrasonography, PET scan, MRI, cytological puncture, myelography, endoscopy).

Genetic screening involved Sanger analysis for familial Mediterranean fever (*MEFV*) gene and/or by next-generation sequencing of a panel of 62 autoinflammatory disease genes (see Additional file [2](#MOESM2){ref-type="media"}).

According to French national regulations, no institutional review board approval was required for this retrospective study.

Cohort characteristics and other variables were analyzed with descriptive statistics (mean ± SD, number \[%\], range) and the Fisher exact test.

Results {#Sec3}
=======

We identified 23 patients (12 girls) with a diagnosis of UCD (*n* = 17) and MCD (*n* = 6) between 1994 and 2018 (Table [1](#Tab1){ref-type="table"}). The patients were seen in 14 centres and the diagnosis was established by paediatric haematologists (*n* = 9), adult immunologists (*n* = 6), paediatric rheumatologists (*n* = 6), a paediatric hepatologist (*n* = 1), an ENT specialist (*n* = 1), or a dermatologist (*n* = 1). Three cases were previously published \[[@CR4]--[@CR6]\]. Table 1General clinical, laboratory and treatments characteristics of the paediatric cohort of unicentric CD (UCD) and multicentric CD (MCD)UCD (*n*=17)MCD (*n*=6)mean±SD (range) or n (%)mean±SD (range) or n (%)Sex ratio (F:M)9/83/3Age at first symptoms (years)11.47 ± 4.23 (0.25-16.5)8.3 ± 3.4 (2.8-13)Diagnosis delay (year)0.68 ± 0.86 (0-3)5.16 ± 5.81 (0-17)Pathological type HV13 (76.5%)0 (0%) PCV3 (17.6%)2 (33.3%) Mixed type0 (0%)3 (50%) No data1 (5.9%)1 (16.6%)At diagnosis Fever3 (17.6%)5 (83.3%) CRP level, mg/L23.4 ± 42.07 (0.5-150)50.68 ± 26.96 (7.1-96) Hb level, g/dL12.53 ± 2.52 (7.1-15.7)10.23 ± 1.68 (8.8-13.6) Platelet count, x10^9^/mm3334.19 ± 151.34 (115-791)319.17 ± 164.32 (141-665) IgG level, g/L12.8 ± 6.96 (6.9-29.7)21.48 ± 7.69 (15-36) HIV serology0 (0%)0 (0%) HHV8 (serology, PCR or immunostaining)0 (0%)0 (0%)Treatment Surgical excision12 (70.6%)0 (0%) Radiotherapy1 (5.9%)0 (0%) Chemotherapy0 (0%)1 (16.7%) Tocilizumab2 (11.8%)5 (83.3%) Anakinra2 (11.8%)1 (16.7%) Steroïds4 (23.5%)3 (50%) Splenectomy0 (0%)1 (16.7%) No treatment3 (17.6%)0 (0%) IgIV1 (5.9%)0 (0%)*CD* Castleman disease, *F* female, *M* male, *HV* hyaline vascular, *PCV* plasma cell variant, *Hb* haemoglobin, *IgG* immunoglobulin G, *IgIV* intravenous immunoglobulin, *CRP* C-reactive protein, *HHV-8* human herpesvirus 8, *SD* standard deviation

For UCD patients, the mean age at first symptoms was 11.47 ± 4.23 years (range 0.25--16.5) and the mean diagnosis delay was 8.16 ± 10.32 months (range 0--36). The initial symptoms were isolated lymph nodes (10/17; 58.8%) or lymph node associated with other symptoms (7/17; 41.2%), and fever was present in only 3/17 (17.6%) patients (Table [2](#Tab2){ref-type="table"}). Serum C-reactive protein (CRP) level was increased (\> 10 mg/l) in 4/16 (25%) patients; the mean CRP level was 23.4 ± 42.07 mg/l (range 0.5--150). Elevated IgG level was observed in 4/12 (33%) patients; the mean IgG level was 12.8 ± 6.96 g/l (range 6.9--29.7). Mean haemoglobin level was 12.53 ± 2.52 g/dl (range 7.1--15.7) (16/17 patients) and mean platelet count 334.19 ± 151.34 × 10^9^/mm^3^ (range 115--791). Diagnostic investigations were lymph node biopsy (16/17; 94%), CT scan (13/17; 76.5%), ultrasonography (10/17; 58.8%), PET scan (7/17; 41.2%), lymph node cytological puncture (4/17; 23.5%), MRI (3/17; 17.6%), myelography (1/17; 5.9%), and upper and lower digestive endoscopy with digestive biopsies (1/17; 5.9%). The most frequent histologic finding on lymph node biopsy was the HV type (*n* = 13/17; 76.5%), then the mixed type (3/17; 17.6%). CD adenopathy was in the cervical area in 11/17 (64.7%) patients, intrathoracic in 4/17 (23.5%), and intraperitoneal in 2/17 (11.8%) (Fig. [1](#Fig1){ref-type="fig"}a). Table 2Clinical and laboratory features of 17 patients with UCDPatient/SexAge at first symptoms (year)Initial symptomsHb g/dlplatelets x10^9^/LIgG g/lCRP mg/lESR mm/hDiagnosis delay (year)Diagnostic investigationsLymph node localizationPathological typeTreatmentsFollow-up time (year)EvolutionGenetic variant**P1 / M**0.25Cervical lymph node11.93718.12\--0.9Ultrasonography, CT scan, lymph node biopsyCervicalHVTocilizumab, steroids, anakinra, surgical excision1.5No relapseND**P2 / F**14Right cervical lymph node13246-\<4100.5CT scan, PET scan, lymph node biopsyCervicalHVSurgical excision1.5No relapseND**P3 / F**10Left cervical lymph node12.8304-642.5Ultrasonography, CT scan, lymph node cytopunction, lymph node biopsyCervicalHVSurgical excision7No relapseND**P4 / M**16.5Oral pemphigus14.9248143-0.5CT scan, PET scan, lymph node biopsyThoracicHVRituximab, steroids, immunoglobulin, surgical excision3No relapseND**P5 / F**14Left cervical lymph node12.8310-0.6-0Ultrasonography, CT scan, MRI, PET scan, lymph node cytopunction, lymph node biopsyCervicalHVSteroids, Surgical excision5No relapseND**P6 / F**15Torsion of an ovarian cyst and hepatosplenomegaly7.179121.289950PET scan, lymph node cytopunctionThoracicNDSteroids, anakinra, tocilizumab and radiotherapy8Reduction of pulmonary lymph node after radiotherapy, which remains persistent, no relapseND**P7 / M**15.5Fever and aseptic meningitis\-\--49610CT scan, lymph node biopsyThoracicMPSurgical excision11No relapse but unexplained fever episodes, pericarditisIL10RA: V406L/WT; IL36RN: S113L/W; MEFV: WT/WT**P8 / M**11.5Fever and sporadic rectal bleeding7.9365211501050.5CT scan, lymph node biopsyPeritonealMPSurgical excision8No relapseND**P9 / F**6Bronchopathy, 2 unilateral cervical lymph nodes13.72858.41-0Ultrasonography, CT scan, lymph node biopsyCervicalHVSurgical excision0.75No relapseND**P10 / M**13Thoracic lymph node14.32379.22-0CT scan, lymph node biopsyThoracicHVNo treatment18Lymph node stabilityND**P11 / F**9Cervical lymph node13.81156.91-1Ultrasonography, CT scan, lymph node biopsyCervicalHVSteroids16No relapseND**P12 / F**123 unilateral cervical lymph nodes13.52308.61-0Ultrasonography, CT scan, lymph node biopsyCervicalHVNo treatment2.8Lymph nodes stability, coeliac diseaseND**P13 / M**15Cervical lymph node14.73109.41-0Ultrasonography, lymph node biopsyCervicalHVSurgical excision2.9No relapseND**P14 / M**5Fever, cervical lymph node evolving since 2 years13.53588.71-3Ultrasonography, PET scan, lymph node biopsyCervicalHVNo treatment0.5Fever remission, lymph nodes stabilityND**P15 / F**10.3Cervical lymph node134348.41-0.8MRI, PET-Scan, lymph node biopsyCervicalHVSurgical excision0.7No relapseND**P16 / M**15Cervical lymph node15.7207-0.521.2Ultrasonography, CT scan, lymph node cytopunction, lymph node biopsy, PET scanCervicalHVSurgical excision1No relapseND**P17 / F**13Abdominal pain, fatigue7.953629.765610.7Ultrasonography, CT scan, MRI, digestive endoscopy with biopsies, myelogram, lymph node biopsiesPeritonealMPSurgical excision3No relapseND*Hb* haemoglobin, *CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *HV* hyaline vascular, *MP* mixed pathology, *ND* no data, *NGS* next-generation sequencing, *WT* wild typeFig. 1**A**: Adenopathy localizations in 17 patients with unicentric Castleman disease; **B**: Histopathologic findings in a multicentric CD patient with plasma cell variant, **B1**: CD138 immunohistochemical staining revealing interfollicular plasma cells, **B2**: hyperplastic interfollicular region of the node with sheets of plasma cells; **C**: Imaging findings in a 4-year-old patient with multicentric CD. **C1**: 2 MRI-detected intra-abdominal masses at diagnosis. **C2**: Decreased but persistent masses at 1 year of treatment with tocilizumab

Twelve of 17 patients underwent surgical lymph node excision (70.6%), 5/17 patients received steroids (29.4%), 3/17 (17.6%) patients received immunomodulatory treatments (tocilizumab = 2, anakinra = 2, rituximab = 1 and intravenous immunoglobulin = 1), 1/17 (5.9%) patient (P6) received radiotherapy and 3/17 (17.6%) patients had no treatments. At last evaluation after a mean follow-up of 5.33 ± 5.21 years (range 0.5--18), 12/17 patients were in complete remission (70.6%), 3/17 patients had a stable adenopathy size without treatment (17.6%), 1/17 (5.9%) patient had a persistent (but decreased) lesion after radiotherapy, and 1/17 (5.9%) patient (P7) still had recurrent fever after surgical resection of the adenopathy. P7 also experienced recurrent episodes of aseptic meningitis, pericarditis, neutropenia, lymphadenopathy, abdominal pain, persistent diarrhoea and interstitial lung disease. Screening for an autoinflammatory gene panel in this patient retrieved a class 2 (likely benign) heterozygous variant in *IL10RA* (V406L) and a pathogenic heterozygous variant in *IL36RN* (S113L) \[[@CR7]\].

For patients with MCD (Table [3](#Tab3){ref-type="table"}), the mean age at the first symptoms was 8.3 ± 3.4 years (range 2.8--13). They presented fever (5/6; 83.3%), abdominal lymph nodes (5/6; 83.3%), failure to thrive (3/6; 50%), hepatomegaly and/or splenomegaly (3/6; 50%), arthralgia (2/6; 33.3%), abdominal pain (2/6; 33.3%), fatigue (2/6; 33.3%), facial oedema (1/6;16.7%), isolated lymphadenopathy (1/6; 16.7%), rash on the trunk (1/6; 16.7%), vascular hepatopathy with oesophageal varicose veins (1/6; 16.7%), diarrhoea (1/6; 16.7%) and cholestasis (1/6; 16.7%). One patient (P23) had autism and Duchenne muscular dystrophy. Serum CRP level was increased in 5/6 (83.3%) patients; the mean CRP level was 50.68 ± 26.96 mg/l (range 7.1--96). Elevated IgG level was detected in 5/5 (100%) patients; the mean IgG level was 21.48 ± 7.69 g/l (range 15--36). The mean haemoglobin level was 10.23 ± 1.68 g/dl (range 8.8--13.6) and mean platelet count 319.17 ± 164.32 × 10^9^/mm^3^ (range 141--665). Table 3Clinical and laboratory features of 6 patients with MCDPatient/SexP18 / FP19 / FP20 / MP21 / FP22 / MP23 / M**Age at first symptoms (years)**137611102.8**Initial symptoms**Left jugular lymph nodeRecurrent fever, arthralgia, hepatomegaly, splenomegaly, abdominal lymph nodes, failure to thrive, fatigue and facial edemaFever, arthralgia, abdominal pain, abdominal lymph nodes and failure to thriveFever, abdominal lymph nodesRecurrent fevers, hepatomegaly, splenomegaly, abdominal pain, abdominal lymph nodes, trunk rash, vascular hepatopathy and oesophageal varicose veinsRecurrent fevers, hepatomegaly, abdominal lymph nodes, failure to thrive, fatigue, diarrhea, cholestasis and Duchenne muscular dystrophy**Haemoglobin level, g/dl**13.6998.810.110.9**Platelet count, x10**^**9**^**/L**261328270250141665**IgG level, g/l**16151822.4-36**CRP level, mg/l**7.16740964648**ESR, mm**205575\--131**Leukocyte count, x10**^**9**^**/L**7.410-78.114.9**Initial diagnosis**-Primary parvovirus infectionStill disease then familial Mediterranean fever-unclassified vasculitis-**Initial treatment**-ColchicineAspirin, methotrexate, colchicine, corticosteroids-Corticosteroids, hydroxychloroquine, colchicine, NSAID, anakinra-**Diagnosis delay (years)**03.57.51172**Diagnostic investigations**PET scan, lymph node biopsyUltrasonography, CT scan, PET scan, liver biopsy, lymph node biopsyCT scan, PET scan, lymph node biopsyUltrasonography, CT scan, lymph node biopsyCT scan, PET scan, lymph node biopsyUltrasonography, CT scan, MRI, lymph node biopsy**Histological type**Mixed pathologyPlasma cell variantMixed pathologyMixed pathologyNDPlasma cell variant**Treatments**TocilizumabTocilizumabChemotherapy (cyclophosphamide and vinblastine), rituximab, steroids, anakinra and tocilizumabSteroids, splenectomyTocilizumabSteroids, tocilizumab**Follow-up time**15 months6 years17 years23 years1 year1 year**Evolution**Complete remission, no relapse at 3 months after the tocilizumab weaningPatial remission, no relapse but persistence of hepatic hypermetabolic signals. Fluctuating lymphopenia and thrombocytopeniaTocilizumab weaning after 4 years of treatment: increased inflammatory markers and headaches. Resumption of tocilizumab allowing for a disappearance of the symptoms. No relapse with tocilizumabComplete remission, no relapsePartial remission, no relapsePartial remission, patient dependent on tocilizumab treatment. Appearance of non-specific inflammatory colitis.**Genetic variant**ND*MEFV*: WT/WT*MEFV*: K695R/WTND*MEFV*: WT/WT*TNFRSF1A*: P75L/P75L; *MEFV*: WT/WT*CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *NSAID* nonsteroidal anti-inflammatory drug, *CT* computerized tomography, *PET* positron emission tomography, *MRI* magnetic resonance imaging, *ND* no data, *NGS* next-generation sequencing, *WT* wild type

Diagnostic investigations were lymph node biopsy (6/6; 100%), CT scan (5/6; 83.3%), PET scan (4/6; 66.7%), ultrasonography (3/6; 50%), MRI (1/6; 16.7%) and liver biopsy (1/6; 16.7%). Other diagnoses considered before CD confirmation were primary parvovirus infection (1/6; 16.7%), familial Mediterranean fever (1/6; 16.7%), Still disease (1/6; 16.7%), and unclassified vasculitis (1/6; 16.7%). The histologic types of CD on lymph node biopsies were mixed subtype for 3/6 (50%) patients and PCV for 2/6 (33.3%) (Fig. [1](#Fig1){ref-type="fig"}b). The mean diagnostic delay was 5.16 ± 5.81 years (range 0--17). All 6 patients fulfilled the diagnosis criteria of idiopathic MCD proposed by Fajgenbaum et al. \[[@CR8]\].

The *MEFV* gene was sequenced in 3/6 (50%) patients. P20 was heterozygous for K695R, and P19 and P22 had no mutations. All three patients showed no response to colchicine treatment. The genetic test in P23, with MCD, revealed a homozygous class 3 variant (P75L) in *TNFRSF1A*.

Patients received tocilizumab (5/6; 83.3%), steroids (3/6; 50%), chemotherapy (1/6; 16.7%), rituximab (1/6; 16.7%), anakinra (1/6; 16.7%) and splenectomy (1/6; 16.7%). The mean follow-up was 8.21 ± 8.69 years (range 1--23). Among the 5 patients who received tocilizumab, at last follow-up, P18 was in remission at 3 months after tocilizumab discontinuation, and 4 patients were still receiving tocilizumab: P19, P22 and P23 were in partial remission after 6 years, 1 year and 1 year, respectively, of tocilizumab, with decreased but persistent lymphadenopathies (Fig. [1](#Fig1){ref-type="fig"}c). P20 had a relapse upon discontinuation of tocilizumab after 4 years of treatment with inflammatory symptoms. Tocilizumab was then successfully reinitiated, with decreased but persistent lymphadenopathy. P21 was in remission after 1 year of steroids and splenectomy; she had no relapse after 23 years of follow-up.

All patients (23/23; 100%) were negative on HIV-1 and HIV-2 serology, and 22/22 (100%) were negative on HHV-8 serology, HHV-8 DNA PCR of blood or LANA1 staining (HHV-8 immunostaining) on biopsy.

Discussion {#Sec4}
==========

Paediatric CD is an extremely rare disease, and its pathogenesis is poorly understood. We identified reference centres in France to gather one of the largest cohorts of paediatric CD reported so far, to build a national registry.

Our patients had an equal sex ratio and underwent much diagnostic wandering and delay. The 2 types of CD differed in delay, with mean diagnostic delay of 8.16 ± 10.32 (range 0--36 months) for UCD and 5.16 ± 5.81 years (range 0--17 years) for MCD. In comparison, in a reference centre for adult CD, the diagnostic delay was t 3 months for MCD and 5.6 months for UCD \[[@CR9]\]. The main reasons for the diagnostic delay in CD are probably the lack of specificity of calling symptoms combined with little awareness of this condition among paediatricians as well as insufficient dialogue with pathologists. Unfortunately, the diagnostic delay has deleterious consequences such as increased morbidity due to chronic inflammation in children, particularly growth retardation, and significant burden related to useless explorations and untimely treatments.

Recently, a group of international experts published criteria for the diagnosis of idiopathic MCD that could help reduce the diagnostic delay \[[@CR8]\]. These criteria include 2 major criteria: a standardized anatomopathological description and number of lymphadenopathies ≥2. Therefore, the diagnosis of MCD is based on a biopsy of a lesion and radiological staging on ultrasonography, CT scan, PET scan and MRI \[[@CR10]\]. The minor criteria encompass many biological and clinical anomalies (11 criteria). Exclusion criteria are infection and oncologic and autoimmune diseases such as systemic lupus erythematosus. Despite these criteria, the differential diagnosis of autoimmune diseases is still difficult because autoantibodies (of systemic lupus erythematosus type) are found in about 30% of idiopathic CD cases \[[@CR11]\]. All our cases of paediatric MCD satisfied these adult criteria of idiopathic MCD. In the future, fluorine-18-fluorodeoxyglucose-PET/MRI could have a role in staging, particularly in children because of the absence of irradiation with this technology as compared with PET or CT scan \[[@CR12]\].

CD more likely presents as UCD (73.9--75% of cases) than MCD in children, whereas UCD represents 20.9% of CD cases in adult cohorts \[[@CR2], [@CR9]\]. Indeed, the disease mechanism may be different because most adult cases occur in a context of immunodeficiency associated with both HIV and HHV-8 infection, unlike in children. HHV-8--associated MCD represents a specific entity in terms of both treatment and prognosis. The association between CD and HHV8 has been reported only once in a child of consanguineous parents without HIV infection and living in an endemic country \[[@CR13]\]. None of our patients was infected with HHV-8.

The role of IL-6 is important in the inflammatory manifestations of CD, which can mimic Still disease, another IL-6--related condition with underlying autoinflammatory mechanisms. IL-6 is secreted by the germinal centres of the lymph nodes in CD patients \[[@CR3]\]. As a result, in our paediatric cohort, 83.3% of MCD patients had fever and mean CRP level of 50.68 ± 26.96 mg/dl (range 7.1--96).

Deregulation of the innate immune system may be critical in the pathogenesis of paediatric CD; this hypothesis was pursued by the investigation of autoinflammatory gene variants in five of our patients. Three underwent *MEFV* screening by Sanger analysis and two next-generation sequencing of a panel of autoinflammatory genes (additional file [2](#MOESM2){ref-type="media"}). Various sequence variants of unknown significance were retrieved in three different genes and in three of the five patients. In 2018, Van Nieuwenhove et al. reported a patient with MCD and adenosine deaminase 2 deficiency \[[@CR14]\]. Overrepresentation of patients with autoinflammatory gene variants in paediatric MCD raises the possibility of amplified innate immune response to undefined triggers. Of note, systemic symptoms are also encountered in paediatric UCD and may be more frequent than in the adult counterpart: 17.6% with fever versus 4.2% without. However, this difference was not significant (*p* = 0.083). CRP level was also higher: 23.4 mg/dL (range 0--150) in children versus 2 mg/dL in adults \[[@CR15]\]. Our results appeared to be similar to those observed in a recently published paediatric cohort of 24 patients \[[@CR2]\] in which 44% of UCD patients had systemic symptoms.

The HV type is the most represented pathological type in paediatric UCD, 76.5%, as compared with adults, 68% \[[@CR9]\]. Even if our patient cohort is small, paediatric patients may present more cervical lymph nodes than adults: 44 to 64.7% in children as compared with 26% in adults \[[@CR2], [@CR9]\].

In MCD patients, PCV and mixed types are the main pathological types in adults and children (77.7 and 83.3%) \[[@CR9]\].

The treatment mainly depends on the CD type. Surgery is the gold standard for treatment of UCD and may be curative in 95% of cases \[[@CR16]\]. A surgical approach may be compromised in certain sites of deep lymphadenopathy or located close to vessels. Pre-surgical treatment may be needed to facilitate total tumour excision, as in our patients P1 and P5, who received corticosteroids and biologic therapies (tocilizumab and anakinra) to reduce the size of cervical lesions before surgery. For unresectable locations, radiotherapy can be discussed, although its long-term toxicity remains an issue, particularly in children. A careful wait-and-watch strategy without treatment can also be proposed \[[@CR15]\]. The approach to paediatric UCD in our cohort appeared to be the same as in adult CD, with 70.5% surgery (vs 66% in adults) and 17.5% wait-and-watch approach (vs 15% in adults). Only one child received radiotherapy (5.8%, vs 11% (8/71) in adults) \[[@CR15]\].

Treatment of MCD, even if possibly not curative, is essential to limit serious complications of chronic inflammation and to improve quality of life \[[@CR11]\]. Until recently, this treatment in adults as in children was not standardized. If surgery was not possible, steroids and chemotherapy were the first treatment used historically, but their efficacy was relatively limited, with a high cost of related toxicities. New therapeutic approaches have emerged, including anti-CD20, anti-IL-1 and anti-IL-6 biologic therapies \[[@CR1], [@CR5]\]. New guidelines were published in 2018 for adult idiopathic MCD, with siltuximab, an anti-IL-6 antibody, and tocilizumab, an anti-IL-6 receptor monoclonal antibody, now first-line treatments \[[@CR17], [@CR18]\]. For many years, tocilizumab was also used in paediatric CD \[[@CR6]\]. In adult CD, tocilizumab allowed for reduction of lymph nodes to \< 10 mm in only 52.2% of patients after 1 year of treatment \[[@CR19]\]. In the same study, CRP and fibrinogen levels were normalized in 64.3 and 71.4% of patients, respectively, after 16 weeks of treatment. We also describe a suspension effect of tocilizumab on the disease in four children, with a complete response in terms of inflammatory symptoms. However, P20 showed a relapse of inflammatory symptoms after discontinuation of tocilizumab after treatment for 4 years, which then had to be resumed. For the other 3 patients, liver damage remained for P19, and decreased size lymphadenopathies persisted in P22 and P23. The question of weaning remains to be studied in children as in adults. However, one of our patients (P18) was in complete remission at 3 months after stopping therapy. Another study reported a total cure after combined chemotherapy followed by tocilizumab and discontinuation of all treatments \[[@CR20]\]. The benefit of IL-6--targeting drugs in CD is not fully known because they have never been included in a comparative drug trial. Nevertheless, the therapeutic attitude in paediatrics now seems to be the same as in adults, with the use of tocilizumab as a first-line treatment for MCD.

Our patients showed 100% survival after a mean of 6 years of follow-up (range 1 month to 23 years), for all types of CD. In adults, the prognosis also seems good in UCD, close to 100%, but quite poor in MCD, with a 35% rate of death at 5 years \[[@CR21]\].

Conclusion {#Sec5}
==========

We report a large cohort of paediatric Castleman's disease, in which, unlike in adults, the unicentric form was the most common. The new diagnostic criteria for idiopathic MCD should be tested in children to reduce the delay to diagnosis. The association of paediatric MCD with autoinflammatory gene variants, rather than HHV-8 and HIV infection, may not be incidental and suggests a primary deregulation of the innate immune system. Il-6--targeting drugs regularly eliminated inflammatory symptoms in our patients, but both treatment duration and long-term safety are still unknown.
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**Additional file 1.** Paediatric Castleman disease data collection questionnaire **Additional file 2.** Next-generation sequencing of a panel of 62 autoinflammatory disease genes.
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